Search

Your search keyword '"Takayama, Hirotaka"' showing total 6 results
Start Over Author "Takayama, Hirotaka" Publication Year Range Last 3 years
6 results on '"Takayama, Hirotaka"'

1. Comparison between single-muscle evaluation and cross-sectional area muscle evaluation for predicting the prognosis in patients with oral squamous cell carcinoma: a retrospective cohort study

Author

Takayama, Hirotaka, primary, Yoshimura, Takuya, additional, Suzuki, Hajime, additional, Hirano, Yuka, additional, Tezuka, Masahiro, additional, Ishida, Takayuki, additional, Ishihata, Kiyohide, additional, Amitani, Marie, additional, Amitani, Haruka, additional, Nakamura, Yasunori, additional, Imamura, Yasushi, additional, Inui, Akio, additional, and Nakamura, Norifumi, additional

Published
2024
Full Text
View/download PDF

2. Exercise Suppresses Head and Neck Squamous Cell Carcinoma Growth via Oncostatin M

Author

Yoshimura, Takuya, primary, Hirano, Yuka, additional, Hamada, Taiji, additional, Yokoyama, Seiya, additional, Suzuki, Hajime, additional, Takayama, Hirotaka, additional, Migita, Hirono, additional, Ishida, Takayuki, additional, Nakamura, Yasunori, additional, Ohsawa, Masahiro, additional, Asakawa, Akihiro, additional, Ishihata, Kiyohide, additional, and Tanimoto, Akihide, additional

Published
2024
Full Text
View/download PDF

3. Prognostic value of inflammatory biomarkers in aged patients with oral squamous cell carcinoma

Author

Yoshimura, Takuya, primary, Suzuki, Hajime, additional, Takayama, Hirotaka, additional, Higashi, Shotaro, additional, Hirano, Yuka, additional, Tezuka, Masahiro, additional, Ishida, Takayuki, additional, Ishihata, Kiyohide, additional, Amitani, Marie, additional, Amitani, Haruka, additional, Nishi, Yasuhiro, additional, Nakamura, Yasunori, additional, Imamura, Yasushi, additional, Nozoe, Etsuro, additional, Inui, Akio, additional, and Nakamura, Norifumi, additional

Published
2022
Full Text
View/download PDF

4. PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland

Author

Yoshimura, Takuya, primary, Higashi, Shotaro, additional, Yamada, Sohsuke, additional, Noguchi, Hirotsugu, additional, Nomoto, Mitsuharu, additional, Suzuki, Hajime, additional, Ishida, Takayuki, additional, Takayama, Hirotaka, additional, Hirano, Yuka, additional, Yamashita, Masaru, additional, Tanimoto, Akihide, additional, and Nakamura, Norifumi, additional

Published
2021
Full Text
View/download PDF

5. Prognostic Role of Preoperative Sarcopenia Evaluation of Cervical Muscles with Long-Term Outcomes of Patients with Oral Squamous Cell Carcinoma

Author

Yoshimura, Takuya, primary, Suzuki, Hajime, additional, Takayama, Hirotaka, additional, Higashi, Shotaro, additional, Hirano, Yuka, additional, Tezuka, Masahiro, additional, Ishida, Takayuki, additional, Ishihata, Kiyohide, additional, Amitani, Marie, additional, Amitani, Haruka, additional, Nishi, Yasuhiro, additional, Nakamura, Yasunori, additional, Imamura, Yasushi, additional, Nozoe, Etsuro, additional, and Nakamura, Norifumi, additional

Published
2021
Full Text
View/download PDF

6. PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland.

Author

Yoshimura, Takuya, Higashi, Shotaro, Yamada, Sohsuke, Noguchi, Hirotsugu, Nomoto, Mitsuharu, Suzuki, Hajime, Ishida, Takayuki, Takayama, Hirotaka, Hirano, Yuka, Yamashita, Masaru, Tanimoto, Akihide, and Nakamura, Norifumi

Subjects
SALIVARY gland tumors, DISEASE progression, EPIDERMAL growth factor, IMMUNOHISTOCHEMISTRY, APOPTOSIS, CELL receptors, GENE expression, TUMORS, TUMOR markers, CELL lines, CARRIER proteins
Abstract

Simple Summary: Mucoepidermoid carcinoma (MEC) is the most common malignancy of all salivary neoplasms, and no effective treatment strategy for MEC has been established other than resection. In this study, we showed that Purkinje cell protein (PCP) 4/peptide (PEP) 19 and human epidermal growth factor receptor 2 (HER2) are predicted to play important roles in the pathogenesis and progression of MEC. The detection of PCP4/PEP19 and HER2 may be useful for providing more effective treatments against MEC. Mucoepidermoid carcinoma (MEC) is one of the most common malignant salivary gland carcinomas, but no effective treatment strategy has been established other than surgical resection. Purkinje cell protein (PCP) 4/peptide (PEP) 19 is a calmodulin-binding antiapoptotic peptide that is expressed and inhibits apoptosis in human breast cancer cells. Human epidermal growth factor receptor 2 (HER2) is an epidermal growth factor that has been implicated in the pathogenesis of many carcinomas, particularly breast and gastric carcinomas. In the present study, we performed immunohistochemical analyses of samples from 73 patients who underwent surgical resection for MEC of the salivary gland using antibodies against PCP4/PEP19 and HER2. PCP4/PEP19 expression was related to better prognosis, while HER2 expression was associated with worse prognosis. Patients that were PCP4/PEP19-positive and HER2-negative showed similar outcomes to PCP4/PEP19 and HER2 alone. Therefore, PCP4/PEP19 and HER2 are predicted to play important roles in the pathogenesis and progression of MEC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results